Granted Patent B2

US 12,410,183 · App. 18/743,475 · Granted Sep 9, 2025

Inventors: Stephen E. Ammann (Foster City, CA); Xinpei Cai (San Mateo, CA); Eda Y. Canales (San Mateo, CA); Weng K. Chang (San Lorenzo, CA); Gregory F. Chin (San Francisco, CA); Henok H. Kinfe (Foster City, CA); Scott E. Lazerwith (San Francisco, CA); Jessica L McKinley (Foster City, CA); Michael R. Mish (Foster City, CA); Devan Naduthambi (San Bruno, CA); Jason K. Perry (San Francisco, CA); Kevin X Rodriguez (San Mateo, CA); Scott D. Schroeder (Union City, CA); Christopher J. Swank (San Mateo, CA); Joshua J. Van Veldhuizen (Seattle, WA)

Assignee: Gilead Sciences, Inc.

C07D495/04A61P31/14C07D401/04C07D401/14C07D405/14C07D409/14C07D413/14C07D417/14C07D471/04C07D487/04C07D487/10C07D491/107C07D491/113C07D498/04C07D513/04C07D519/00

Abstract

Claims (38)

1. A method of treating or preventing a viral infection in a human in need thereof, wherein the method comprises administering to the human a compound selected from

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

11. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

13. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

14. The method of claim 1 , wherein the viral infection is a coronavirus infection.

15. The method of claim 4 , wherein the viral infection is a coronavirus infection.

16. The method of claim 5 , wherein the viral infection is a coronavirus infection.

17. The method of claim 11 , wherein the viral infection is a coronavirus infection.

18. The method of claim 1 , wherein the viral infection is caused by a virus having at least 70% sequence homology to a viral polymerase selected from SARS-CoV polymerase, MERS-CoV polymerase, and SARS-CoV-2.

19. The method of claim 4 , wherein the viral infection is caused by a virus having at least 70% sequence homology to a viral polymerase selected from SARS-COV polymerase, MERS-CoV polymerase, and SARS-CoV-2.

20. The method of claim 5 , wherein the viral infection is caused by a virus having at least 70% sequence homology to a viral polymerase selected from SARS-COV polymerase, MERS-CoV polymerase, and SARS-CoV-2.

21. The method of claim 11 , wherein the viral infection is caused by a virus having at least 70% sequence homology to a viral polymerase selected from SARS-COV polymerase, MERS-CoV polymerase, and SARS-CoV-2.

22. The method of claim 1 , wherein the viral infection is SARS-CoV-2 infection (COVID-19).

23. The method of claim 4 , wherein the viral infection is SARS-CoV-2 infection (COVID-19).

24. The method of claim 5 , wherein the viral infection is SARS-CoV-2 infection (COVID-19).

25. The method of claim 11 , wherein the viral infection is SARS-CoV-2 infection (COVID-19).

Assignments (1)

Continuity (9)

References Cited (90)